Showing results (241-250 of 974) with videos related to

Sort By:
Pageof 98
International Journal of Tissue Reactions|January 1, 1983
Some metabolic and biochemical alterations during the development of stress ulcers in rats forced to swimL Nagy, M Fiegler, G Mózsik, et al.
Toxicology and Applied Pharmacology|August 10, 1999
Influence of tumor necrosis factor-alpha and silibin on the cytotoxic action of alpha-amanitin in rat hepatocyte cultureC El-Bahay, E Gerber, M Horbach, et al.
Lung Cancer (Amsterdam, Netherlands)|February 10, 2026
Participation in lung cancer biospecimen studies: an analysis of the ECOG-ACRIN phase 3 E1505 and E5508 clinical trialsYating Wang, Zhuoxin Sun, Arthi Sridhar, et al.
Clinical and Translational Science|January 16, 2015
Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?M E Blair Holbein, Jelena P Berglund, Kevin Weatherwax, et al.
Nucleic Acids Research|May 27, 1986
Complete nucleotide and derived amino acid sequence of cDNA encoding the mitochondrial uncoupling protein of rat brown adipose tissue: lack of a mitochondrial targeting presequenceR G Ridley, H V Patel, G E Gerber, et al.
Clinical Chemistry|June 18, 2026
Predictive Biomarkers for Immune Checkpoint Inhibitor Efficacy: Challenges, Innovations, and a Pathway to Precision Medicine in the Era of Cancer ImmunotherapyMatthew Lee, Jeffrey A SoRelle, Arun Everest-Dass, et al.
Cancer Journal (Sudbury, Mass.)|December 10, 2020
Immunotherapy Use in Patients With Lung Cancer and ComorbiditiesMitchell S von Itzstein, Amrit S Gonugunta, Helen G Mayo, et al.
Frontiers in Pharmacology|March 22, 2024
CBA (4-chloro-2-(2-chlorophenoxy)acetamido) benzoic acid) inhibits TMEM206 mediated currents and TMEM206 does not contribute to acid-induced cell death in colorectal cancer cellsSven Kappel, Korollus Melek, Daniela Ross-Kaschitza, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 11, 2020
Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLCThomas E Stinchcombe, Robert C Doebele, Xiaofei Wang, et al.
Cancer|December 13, 2006
Venous thromboembolism occurs infrequently in meningioma patients receiving combined modality prophylaxisDavid E Gerber, Jodi B Segal, Amandeep Salhotra, et al.
Pageof 98